Fate Therapeutics
Skip to content
  • About Us
    • Our Mission
    • Our Cells of Interest
    • Management
    • Board of Directors
  • Pipeline
    • Overview
    • Immuno-Oncology Candidates
      • FT500
      • FT516
      • FT596
      • FT538
      • FT576
      • FT819
    • Immuno-Regulation Candidates
      • ProTmune™
      • FT301
  • Science
    • Ex Vivo Cell Modulation
    • iPSC Platform
    • Manufacturing
    • Publications
  • Collaborations
  • Join Our Team
    • Vision, Mission, Values
    • Working at Fate
    • Career Opportunities
  • Investors
    • Overview
    • Press Releases
    • Events & Presentations
    • Financials & Filings
      • SEC Filings
      • Annual Reports and Proxies
    • Corporate Governance
    • Stock Information
      • Historical Stock Lookup
    • Investors FAQs
  • Contact
  • About Us
    • Our Mission
    • Our Cells of Interest
    • Management
    • Board of Directors
  • Pipeline
    • Overview
    • Immuno-Oncology Candidates
      • FT500
      • FT516
      • FT596
      • FT538
      • FT576
      • FT819
    • Immuno-Regulation Candidates
      • ProTmune™
      • FT301
  • Science
    • Ex Vivo Cell Modulation
    • iPSC Platform
    • Manufacturing
    • Publications
  • Collaborations
  • Join Our Team
    • Vision, Mission, Values
    • Working at Fate
    • Career Opportunities
  • Investors
    • Overview
    • Press Releases
    • Events & Presentations
    • Financials & Filings
      • SEC Filings
      • Annual Reports and Proxies
    • Corporate Governance
    • Stock Information
      • Historical Stock Lookup
    • Investors FAQs
  • Contact
2017, conference

Closing Thoughts & Consideration for Developing NK Cell Cancer Immunotherapies

2017, conference

Development of CAR-NK Cell Therapy Product Candidates from Master Pluripotent Cell Lines

2017, conference

iPSC-derived NK Cell Therapy Product Candidates for Solid and Liquid Tumors

2017, conference

NK Cell Properties and the Unique Function of Adaptive Memory NK Cells

2017, conference

Novel Strategies to Activate and Target NK Cells for Cancer

2017, conference

Introduction to Off-the-Shelf NK Cell Cancer Immunotherapy

©2021 Fate Therapeutics | 3535 General Atomics Court, Suite 200, San Diego 92121 | 866.875.1833 | LEGAL

  • About Us
    • Our Mission
    • Our Cells of Interest
    • Management
    • Board of Directors
  • Pipeline
    • Overview
    • Immuno-Oncology Candidates
      • FT500
      • FT516
      • FT596
      • FT538
      • FT576
      • FT819
    • Immuno-Regulation Candidates
      • ProTmune™
      • FT301
  • Science
    • Ex Vivo Cell Modulation
    • iPSC Platform
    • Manufacturing
    • Publications
  • Collaborations
  • Join Our Team
    • Vision, Mission, Values
    • Working at Fate
    • Career Opportunities
  • Investors
    • Overview
    • Press Releases
    • Events & Presentations
    • Financials & Filings
      • SEC Filings
      • Annual Reports and Proxies
    • Corporate Governance
    • Stock Information
      • Historical Stock Lookup
    • Investors FAQs
  • Contact